To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register-based cohort study
Örebro University, School of Medical Sciences. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Epidemiology and Public Health, University College London, London WC1E 7HB, UK.ORCID iD: 0000-0001-6328-5494
Örebro University, School of Medical Sciences. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0003-1030-3470
School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Örebro University, School of Health Sciences. Department of Obstetrics and Gynaecology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0002-2691-7525
Show others and affiliations
2024 (English)In: Brain Communications, E-ISSN 2632-1297, Vol. 6, no 6, article id fcae406Article in journal (Refereed) Published
Abstract [en]

Demyelinating diseases including multiple sclerosis are associated with prior infectious exposures, so we assessed whether SARS-CoV-2 infection is associated with subsequent diagnoses of non-multiple sclerosis demyelinating diseases and multiple sclerosis. All residents of Sweden aged 3-100 years were followed between 1 January 2020 and 30 November 2022, excluding those with demyelinating disease prior to 2020, comprising 9 959 818 individuals divided into uninfected and those who were infected were categorized into those with and without hospital admission for the infection as a marker of infection severity. Cox regression assessed the risk of two separate outcomes: hospital diagnosed non-multiple sclerosis demyelinating diseases of the CNS and multiple sclerosis. The exposures were modelled as time-varying covariates (uninfected, infection without hospital admission and infected with hospital admission). Hospital admission for COVID-19 was associated with raised risk of subsequent non-multiple sclerosis demyelinating disease, but only 12 individuals had this outcome among the exposed, and of those, 7 has an unspecified demyelinating disease diagnosis. Rates per 100 000 person-years (and 95% confidence intervals) were 3.8 (3.6-4.1) among those without a COVID-19 diagnosis and 9.0 (5.1-15.9) among those admitted to hospital for COVID-19, with an adjusted hazard ratio and (and 95% confidence interval) of 2.35 (1.32-4.18, P = 0.004). Equivalent associations with multiple sclerosis (28 individuals had this outcome among the exposed) were rates of 9.5 (9.1-9.9) and 21.0 (14.5-30.5) and an adjusted hazard ratio of 2.48 (1.70-3.61, P < 0.001). Only a small number of non-multiple sclerosis demyelinating disease diagnoses were associated with hospital admission for COVID-19, and while the number with multiple sclerosis was somewhat higher, longer duration of follow-up will assist in identifying whether the associations are causal or due to shared susceptibility or surveillance bias, as these diseases can have long asymptomatic and prodromal phases.

Place, publisher, year, edition, pages
Oxford University Press, 2024. Vol. 6, no 6, article id fcae406
Keywords [en]
SARS-CoV-2, demyelinating disease, multiple sclerosis
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-117761DOI: 10.1093/braincomms/fcae406ISI: 001374598800001PubMedID: 39659973Scopus ID: 2-s2.0-85212132182OAI: oai:DiVA.org:oru-117761DiVA, id: diva2:1920836
Funder
NyckelfondenForte, Swedish Research Council for Health, Working Life and Welfare
Note

This study was funded by grants from Nyckelfonden. The SCIFI-PEARL project has basic funding based on grants from the Swedish state under the agreement between the Swedish government and the county councils, the Avtal om läkarutbildning och forskning/Medical Training and Research Agreement (grant nos. ALFGBG-938453, ALFGBG-971130 and ALFGBG-978954), and previously from a joint grant from Forskningsrådet för hälsa, arbetsliv och välfärd/Research Council for Health, Working Life, and Welfare and Forskningsrådet för miljö, areella näringar och samhällsbyg-gande/Research Council for Environment, Agricultural Sciences and Spatial Planning (grant no. 2020-02828).

Available from: 2024-12-12 Created: 2024-12-12 Last updated: 2025-01-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Montgomery, ScottVingeliene, SBackman, HelenaUdumyan, RuzanJendeberg, JohanRasmussen, GunlögSundqvist, MartinFall, KatjaHiyoshi, Ayako

Search in DiVA

By author/editor
Montgomery, ScottVingeliene, SBackman, HelenaUdumyan, RuzanJendeberg, JohanRasmussen, GunlögSundqvist, MartinFall, KatjaHiyoshi, Ayako
By organisation
School of Medical SciencesSchool of Health SciencesÖrebro University Hospital
In the same journal
Brain Communications
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 96 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf